|
NCT04387240
|
Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19 |
Not yet recruiting |
Phase 2 |
Jan/01/2022 |
Dec/01/2022 |
- Alternative id - 20-0192
- Interventions - Drug: Artemisinin / Artesunate|Other: placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 22
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - length of stay in hospital|number of ICU admission|resolution of symptoms
|
|
NCT04801017
|
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects |
Not yet recruiting |
Phase 2 |
Apr/01/2021 |
Oct/01/2021 |
- Alternative id - C002 2020 01
- Interventions - Drug: OT-101|Drug: Artemisinin|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 18
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - The proportion of subjects with clinical improvement score measured by an 8-point WHO COVID-19 Clinical Improvement Ordinal Scale as assessed by the odds ratio (OR) at Day 14.|The OR at Days 7, 21, and 28 based on the clinical improvement score (as measured by an 8 point WHO COVID 19 Clinical Improvement Ordinal Scale).|The OR at Days 7, 14, 21, and 28 of a decrease of at least 1, 2, 3, and 4 points in subjects with severe COVID 19.|Time to at least 2 point improvement from baseline on Days 7, 14, 21, and 28 in subjects with severe COVID 19.|Worsening (increase in clinical improvement score) of at least '1' score on Days 7, 14, 21, and 28.|Mortality by Days 7, 14, 21, and 28.|Duration of supplemental oxygen/ventilator support by Days 7, 14, 21, and 28.|Duration of intensive care unit stay by Days 7, 14, 21, and 28.|Duration of hospitalization by Days 7, 14, 21, and 28.|Ventilator free days by Day 14 and Day 28.|Days on ventilation.
|
|
NCT05004753
|
A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects |
Completed |
Phase 4 |
Sep/30/2020 |
Apr/30/2021 |
- Alternative id - ARTI/WBPL/P4/2020/01
- Interventions - Dietary Supplement: Artemisinin|Drug: Dexamethasone
- Study type - Interventional
- Study results - No Results Available
- Locations - Government Medical College & Government General Hospital, Srikakulam, Srikakulam, Andhra Pradesh, India|Rajarshi Chhatrapati Shahu Maharaj Government Medical college and Chhatrapati Pramila Raje Hospital, Kolhapur, Maharashtra, India|Seven Star Hospital, Nagpur, Maharashtra, India
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 120
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - Safety Assessments|Efficacy Assessments
|
|
NCT04553705
|
Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19) |
Recruiting |
Phase 2|Phase 3 |
Sep/20/2020 |
Dec/04/2020 |
- Alternative id - TQ/Omega-3 on COVID-19|DOI: 10.31219/osf.io/u56fc
- Interventions - Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator
- Study type - Interventional
- Study results - No Results Available
- Locations - Maternity and Children hospital, Mecca, Makkah, Saudi Arabia
- Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 25 Years to 40 Years (Adult)
- Outcome measures - Clinical improvement|Recovery rate from positive to negative swaps|Fever to normal temperature in days|Remission of lung inflammation in CT or X-ray|Length of hospitalization|(PCR levels) polymerase chain reaction assay levels|Respiratory indexes|C-reactive protein mg/L|Serum Ferritin ng/ml|Lactic acid dehydrogenase U/L|leukocytes count μl|Lipid profile [LDL, HDL, Total cholesterol ]|total plasma antioxidant capacity
|
